Al in Pathology Market: Growth, Size, Share, and Trends

Report Code HIT 8721
Published in Nov, 2024, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Al in Pathology Market by Neural Network (GAN, CNN, RNN), Function (Diagnostic, Image Analysis, CDSS, Data Management, Analytics), Use Case (Drug Discovery, Clinical workflow), End User (Hospital, Labs, Pharma/Biotech), & Region - Global Forecast to 2029

Overview

The global AI in pathology market is projected to reach USD 169.8 million by 2029 from USD 82.8 million in 2024, at a CAGR of 15.4 % over the forecast period. Al algorithms can now be applied to scanning digital pathology images to identify and characterize different anomalies such as tumors, cancerous cells, and structures in tissue that could help pathologists identify and quantify the critical features that could aid in better diagnosis and the decision to start treatment. Al in pathology provides several advantages, such as accurate results, efficiency, and better patient care. This system can help pathologists to detect and characterize abnormalities, make diagnoses, and predict the outcomes of the disease through large datasets and algorithms that are trained by annotated pathology images.

Integration of AI in multiplex imaging, adoption of cloud-based AI platforms in pathology, increasing use of automated AI-assisted QC systems, and rising FDA approvals for AI/ML systems are some of the major factors accelerating market growth. Some of the other growth drivers for the market include a growing demand for higher technology solutions, rising levels of misdiagnoses, increased funding programs to improve the standard of care towards patients, and a growing emphasis on cost containment along with hospital operation efficiency.

Attractive Opportunities in the Al in Pathology Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to government healthcare initiatives and AI policy support, R&D investments by key players and startups, and expanding healthcare infrastructure and hospital digitization.

Surge in collaborations between AI startups and healthcare institutions, and widespread deployment of AI-integrated digital pathology in cancer centers are key factors driving the market growth.

The expansion of AI-enabled diagnostic services in rural and underserved areas and the integration of AI in national cancer screening programs are factors expected to provide lucrative opportunities for market players.

The Asia Pacific AI in pathology market is expected to witness significant growth over the forecast period. due to increasing demand for precision medicine.

Limited digital infrastructure in developing countries and a shortage of skilled personnel are expected to pose a challenge to the growth of this market.

Global Al in Pathology Market Dynamics

DRIVER: Increasing cases of misdiagnosis lead to a growing need for Al in pathology

Misdiagnosis can occur when a disease or condition is either missed, misclassified, or delayed in its diagnosis. This has been such a big problem in healthcare since it leads to the provision of suboptimal and late treatment and also harm to patients, as well as increased healthcare costs. Prostate cancer, breast cancer, and thyroid cancer have proven to be among the most common cancers that are being misdiagnosed. According to a journal published in 2023 by BMJ-Quality & Safety, it is estimated that an estimated total of 800,000 Americans have wrong diagnoses yearly causing the death of 371,000 patients and permanent disabilities to 424,000.

The most common reasons for the misdiagnoses included the interpretation of scans by general pathologists instead of subspecialists, non-ordering of the necessary follow-up test by physicians, and errors made by doctors in interpreting the test results. Artificial intelligence, although still in its infancy in clinical practice, could help with the rising workloads of pathologists while simultaneously providing consistent and timely diagnostic care.

RESTRAINT: High cost of digital pathology systems

One of the reasons for low adoption of Al is a high upfront investment in establishing digital pathology systems: Al often depends on such systems for data acquisition and analysis. A typical digital pathology system will include a slide scanner, an image server, and the relevant software. These can often cost between USD 500,000 and USD 1,500,000. A full-featured scanner itself costs around USD 250,000. The average price of a digital pathology scanner in the Asia Pacific is around USD 110,000 to USD 130,000. Although large hospitals with good capital budgets can afford these systems, not very many pathologists or institutes have limited budgets or even IT support. Healthcare providers are financially constrained much more to invest in expensive technologies like digital pathology, which is most prominently found in emerging countries like India, Brazil, and Mexico. Furthermore, skilled manpower is required for the smooth management and servicing of these digital pathology systems. The prices of the digital pathology systems are supplemented by the lack of scarcity of skilled manpower to operate the digital pathology systems which is most likely to limit the adoption of the systems. Without the adoption of these systems, Al will not be able to get incorporated into pathology.

There are only a few labs in the world that are totally digital now. Some nations, such as the Netherlands or Scandinavian countries, are ahead of the curve in this area. However, in Germany or the US, the transition to digital pathology in the clinical setting is moving at a glacial pace, and so is the adoption of Al in pathology.

 

OPPORTUNITY: Growing demand for personalized medicine

Personalized medicine offers tailored treatments and prevention procedures to each individual's condition for maximum results. The adoption of this kind of medicine is on the rise due to an increase in the population aged at 65 years and above besides an increase incidence of diseases like cancer. For all these disease conditions, personalized medicine offers the opportunity for targeted therapies aimed to destroy tumor cells with minimal impact on healthy cells. According to this report, out of the 48 novel therapeutic molecular entities approved by the US FDA in 2021, 17, alongside two new cell-based therapies, were personalized medicine. Around 47% of these newly accepted personalized therapies were indicated for the treatment of cancers. A few of the important developments concerning the application of Al in pathology for personalized medicine are listed below:

  • In September 2024, Paige Al, Inc. launched Paige Alba, an Al tool developed as a clinical-grade multimodal co-pilot to advance personalized medicine and precision oncology. It provides real-time Al-driven insights for patients.
  • In March 2022, Ibex Medical Analytics Ltd. partnered with Dedalus Group. Through this partnership, the company can bring the power of artificial intelligence to digital pathology.

In personalized medicine, pathological data is required to prescribe the right therapy at the right time. Al in pathology systems offers companion algorithms for specimen slide diagnosis, which helps detect cancer cells and enable early diagnosis. Thus, the high demand for personalized medicine offers significant growth opportunities for Al in the pathology market.

CHALLENGES: Data privacy concerns

The adoption of Al in industry is limited by data privacy. In most countries, patient health information is covered under federal laws and compromises in its safety may attract litigation and financial responses. As Al used for patient care requires access to multiple health datasets, Al-based tools need to adhere to all the data security protocols implemented by governments and regulatory authorities. This is a difficult task as most Al platforms are consolidated and require extensive computing power, owing to which patient data, or parts of it, can be required to reside in a vendor's data center. The need to alleviate concerns regarding data privacy by ensuring sufficient security remains a major challenge in the market. The figure below shows the percentage of healthcare breaches reported to the US Department of Health and Human Services involving 500 or more individuals.

Global Al in Pathology Market Ecosystem Analysis

The AI in pathology ecosystem is a network involving complex distributions with various stakeholders in the process who have all contributed to the product so far. The key players for this ecosystem are AI software providers and cloud service providers, which provide scalable data platforms for hosting and processing them to cut across large data outputs from high-resolution images with diagnostics. The medical device manufacturers offer the hardware like high-resolution scanners and the imaging systems; middleware providers ensure integration with existing healthcare systems for AI solutions. Also, regulatory bodies decide on the guidelines and pathways of approvals so that the developed AI applications are safe and can comply with their standards. Data analytics solution providers convert pathology data into actionable insights to enable better decisions. This represents an interconnected ecosystem where collaboration would occur among all the technology, healthcare, and regulatory sectors to drive innovation and promote AI adoptions in pathology.

 

By offering, end-to-end solutions (integrated platforms) segment accounted for the largest segment in the AI in pathology market in 2023.

The global AI in pathology market is divided into end-to-end solutions (integrated platforms), niche point solutions, and technology. In 2023, the end-to-end solutions (integrated platforms), segment held the largest share in the global AI in pathology market. This fairly large share can be associated with the relative acceptance and use of Al-based software among pathologists.

It has many advantages, such as great adaptability and interoperability, with the automation of various pathology tasks like image analysis, data extraction, and report generation. Factors that define the adoption and advancement of Al software in pathology pose significant potential for an advance in the detection, diagnosis, and treatment of diseases.

Convolutional Neural Network is estimated to be the fastest-growing segment in the Al in pathology market

The Al in pathology market is segmented into types of neural networks, namely, Generative Adversarial Network (GAN), Convolutional Neural Network (CNN), Recurrent Neural Network (RNN), and others. The convolutional neural network segment is projected to be the fastest-growing segment over the forecast period. This segment has shown phenomenal growth, mainly due to its excellent capability to analyze complex visual data, including pathology images, extract relevant features, and provide correct diagnoses. Apart from that, CNN can locate or section out areas of interest within images and also continuously learn and enhance its performance based on new data and feedback from pathologists.

North America to witness the highest growth rate during the forecast period.

The region leading the pathology AI market, North America, is driven by existing infrastructural developments within the healthcare system, favorable regulations as well as the readiness of the market to accept such technologies as advanced diagnostics. The US and Canada are at the forefront of investing in diagnostics particularly digital pathology and artificial intelligence (AI) technologies aimed at improving diagnosis accuracy and efficiency, especially towards challenging diseases like cancer. While these and other initiatives such as the US FDA's fast-tracked approval of advanced medical equipment like ‘AI by the NCI, have spurred the pathology market to embrace AI technologies quicker than any other market. Moreover, there is also interaction between technology companies and healthcare providers aimed at coming up with these solutions in North America which is also aided by government and private funding

HIGHEST CAGR MARKET IN 2023
NORTH AMERICA FASTEST GROWING MARKET IN THE REGION

Recent Developments of Al in Pathology Market

  • In August 2023, Indica Labs Inc. launched Lung Macrodissect AI tool that transforms slide macrodissection and molecular pathology workflows.
  • In February 2024, Roche Tissue Diagnostics (RTD) collaborated with PathAI to create AI-powered digital pathology algorithms for RTD's companion diagnostics division. These image analysis algorithms are planned to be implemented on Roche’s Navify Digital Pathology platform, ensuring smooth integration into pathology labs across the globe.
  • In February 2024, the US Food and Drug Administration (FDA) approved Hologic Inc.’s Genius Digital Diagnostics System with its AI algorithm features. This system is the first FDA-approved digital cytology solution that integrates deep-learning AI with advanced volumetric imaging technology to assist in detecting pre-cancerous lesions and cervical cancer cells.
  • In January 2022, Aiforia Technologies Plc collaborated with the Mayo Clinic to establish AI-powered pathology research support architecture at Mayo Clinic to enable faster results and scalable studies in translational research.

Key Market Players

Want to explore hidden markets that can drive new revenue in Al in Pathology Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2029
Base Year Considered 2023
Forecast period 2024-2029
Forecast units Million/Billion (USD)
Segments covered Offering, Neural Networks, Functions, Use Case, End User
Geographies covered North America, Europe, Asia Pacific, Latin America, and Middle East and Africa

 

Key Questions Addressed by the Report

Which are the top industry players in the global AI in pathology market?
Koninklijke Philips N.V. (Netherlands), F. www Hoffmann-La Roche Ltd (Switzerland), Hologic, Inc. (US), Akoya Biosciences, Inc. (US), Aiforia Technologies Plc (Finland), Indica Labs Inc. (US), OptraScan (US), Ibex Medical Analytics Ltd. (Israel), Mindpeak GmbH (Germany), Tribun Health (France), Techcyte, Inc. (US), Deep Bio Inc. (Korea), Lumea Inc. (US), Visiopharm (Denmark), aetherAl (Taiwan), Aiosyn (Netherlands), Paige Al, Inc. (US), Proscia Inc. (US), PathAl, Inc. (US), Tempus Labs, Inc. (US), Konfoong Biotech International Co., Ltd. (China), DoMore Diagnostics AS (Norway), Verily Life Sciences, LLC (US), deepPath (US), and 4D Path Inc (US).
Which offerings have been included in the AI in pathology market report?
This report contains the following AI in pathology offering:
  • End-to-end Solutions
  • Niche Point Solutions
  • Technology
  • Hardware
    • Scanners
    • Microscopes
    • Storage Systems
Which geographical region is dominating in the global AI in pathology market?
The global AI in pathology market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America holds the largest share, and it also projected to register the highest growth during the forecast period.
Which end-user segments have been included in the AI in pathology market report?
The report contains the following end-user segments:
  • Pharmaceutical & Biopharmaceutical Companies
  • Hospitals & Reference Laboratories
  • Academic & Research Institutes
What is the total CAGR expected to be recorded for the AI in pathology market during 2024-2029?
The CAGR is expected to record a CAGR of 15.4 % from 2024-2029

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Al in Pathology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
1
RESEARCH METHODOLOGY
15
EXECUTIVE SUMMARY
35
PREMIUM INSIGHTS
56
MARKET OVERVIEW
68
  • 5.1 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
  • 5.2 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.3 INDUSTRY TRENDS
    EVOLUTION OF AI IN PATHOLOGY
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - MACHINE LEARNING (ML) and DEEP LEARNING (DL)
    - COMPUTER VISION
    COMPLEMENTARY TECHNOLOGY
    - CLOUD COMPUTING
    ADJACENT TECHNOLOGIES
    - TELEPATHOLOGY
  • 5.7 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY ANALYSIS
    - NORTH AMERICA
    - EUROPE
    - ASIA PACIFIC
  • 5.8 PRICING ANALYSIS
    AVERAGESELLING PRICE TREND OF KEY PLAYERS, BY OFFERING
    AVERAGE SELLING PRICE TREND, BY REGION
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
  • 5.10 PATENT ANALYSIS
    PATENT PUBLICATION TRENDS FOR THE AI IN PATHOLOGY MARKET
    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.12 END USER ANALYSIS
    UNMET NEEDS
    END-USER EXPECTATIONS
  • 5.13 KEY CONFERENCES & EVENTS IN 2024-2025
  • 5.14 CASE STUDY ANALYSIS
  • 5.15 AI IN PATHOLOGY MARKET: INVESTMENT AND FUNDING SCENARIO
  • 5.16 AI IN PATHOLOGY MARKET: BUSINESS MODELS
  • 5.17 IMPACT OF AI/GEN AI IN THE AI IN PATHOLOGY MARKET
AI IN PATHOLOGY MARKET, BY OFFERING, 2022–2029 (USD MILLION)
76
  • 6.1 INTRODUCTION
  • 6.2 END-TO-END SOLUTIONS (INTEGRATED PLATFORMS)
  • 6.3 NICHE POINT SOLUTIONS
  • 6.4 TECHNOLOGY
  • 6.5 HARDWARE
    SCANNERS
    MICROSCOPES
    STORAGE SYSTEMS
AI IN PATHOLOGY MARKET, BY NEURAL NETWORKS 2022–2029 (USD MILLION)
89
  • 7.1 INTRODUCTION
  • 7.2 GENERATIVE ADVERSARIAL NETWORK (GANS)
  • 7.3 CONVOLUTIONAL NEURAL NETWORK (CNNS)
  • 7.4 RECURRENT NEURAL NETWORK (RNNS)
  • 7.5 OTHERS
AI IN PATHOLOGY MARKET, BY FUNCTIONS 2022–2029 (USD MILLION)
97
  • 8.1 INTRODUCTION
  • 8.2 IMAGE ANALYSIS
  • 8.3 DIAGNOSTICS
  • 8.4 WORKFLOW MANAGEMENT
  • 8.5 DATA MANAGEMENT
  • 8.6 PREDICTIVE ANALYTICS
  • 8.7 CDSS
  • 8.8 AUTOMATED REPORT GENERATION
  • 8.9 QUALITY ASSURANCE TOOLS
AI IN PATHOLOGY MARKET, BY USE CASE 2022–2029 (USD MILLION)
115
  • 9.1 INTRODUCTION
  • 9.2 DRUG DISCOVERY
    TARGET IDENTIFICATION & SELECTION
    TARGET VALIDATION
    HIT IDENTIFICATION &PRIORITIZATION
    HIT-TO-LEAD IDENTIFICATIION
    LEAD OPTIMIZATION
    CANDIDATE SELECTION&VALIDATION
  • 9.3 DISEASE DIAGNOSIS AND PROGNOSIS
  • 9.4 CLINICAL WORKFLOW
  • 9.5 TRAINING & EDUCATION
AI IN PATHOLOGY MARKET, BY END USER, 2022–2029 (USD MILLION)
134
  • 10.1 INTRODUCTION
  • 10.2 PHARMACUETICAL AND BIOPHARMECUETICAL COMPANIES
  • 10.3 HOSPITAL AND REFERENCE LABORATORIES
  • 10.4 ACADEMIC AND RESEARCH INSTITUTES
AI IN PATHOLOGY MARKET, BY REGION
146
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    CANADA
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    FRANCE
    UK
    ITALY
    SPAIN
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    JAPAN
    INDIA
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    MEXICO
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
188
  • 12.1 OVERVIEW
  • 12.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • 12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • 12.6 VALUATION AND FINANCIAL METRICS OF KEY AI IN PATHOLOY VENDORS
  • 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT, KEY PLAYERS, 2023
    - COMPANY FOOTPRINT
    - REGION FOOTPRINT
    - OFFERING FOOTPRINT
    - TECHNOLOGY FOOTPRINT
    - THERAPEUTIC AREA FOOTPRINT
    - PROCESS FOOTPRINT
    - USE CASE FOOTPRINT
    - DEPLOYMENT FOOTPRINT
    - END-USER FOOTPRINT
  • 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    - DETAILED LIST OF STARTUPS/SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • 12.9 COMPETITIVE SCENARIO AND TRENDS
    PRODUCT LAUNCHES
    DEALS
    OTHERS
COMPANY PROFILES
198
  • 13.1 KEY PLAYERS
    KONINKLIJKE PHILIPS N.V.
    F. HOFFMANN-LA ROCHE LTD
    HOLOGIC, INC.
    AKOYA BIOSCIENCES, INC.
    AIFORIA
    INDICA LABS INC.
    OPTRASCAN
    IBEX MEDICAL ANALYTICS LTD.
    MINDPEAK GMBH
    TRIBUN HEALTH.
    TECHCYTE, INC.
    DEEP BIO INC.
    LUMEA INC.
    VISIOPHARM
    AETHERAI
    AIOSYN
    PAIGE AI, INC.
    PROSCIA INC.
    PATHAI, INC.
    TEMPUS LABS, INC.
    KONFOONG BIOTECH INTERNATIONAL CO., LTD.
    DOMORE DIAGNOSTICS AS
    VERILY LIFE SCIENCES, LLC
    DEEPPATH
    4D PATH INC. PATHAGILITY
APPENDIX
219
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 AVAILABLE CUSTOMIZATIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS

This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.

Secondary Research

This research study involved the wide use of secondary sources, directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, white papers, annual reports, and companies’ house documents. Secondary research was undertaken to identify and collect information for this extensive, technical, market-oriented, and commercial study of the AI in pathology market. It was also used to obtain important information about the top players, market classification, and segmentation according to industry trends to the bottom-most level, geographic markets, and key developments related to the market. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the AI in pathology market. Primary sources from the demand side included personnel from pharmaceutical & biopharmaceutical companies, research institutes, and hospitals (small, medium-sized, and large hospitals).

A breakdown of the primary respondents is provided below:

*C-level primaries include CEOs, CFOs, COOs, and VPs.

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = < USD 1.00 billion.

Source: MarketsandMarkets Analysis

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the AI in pathology market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

The size of the AI in pathology market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as given below:

  • Revenues for individual companies were gathered from public sources and databases.
  • Shares of leading players in the AI in pathology market were gathered from secondary sources to the extent available. In certain cases, shares of AI in pathology businesses have been ascertained after a detailed analysis of various parameters including product portfolios, market positioning, selling price, and geographic reach & strength. 
  • Individual shares or revenue estimates were validated through interviews with experts.
  • The total revenue in the AI in pathology market was determined by extrapolating the Market share data of major companies.

Market Definition

The AI in pathology market refers to the commercial space where companies develop, market, and provide products and services that incorporate artificial intelligence technologies specifically designed for pathology applications. This market focuses on leveraging AI algorithms, machine learning techniques, and advanced computational tools to enhance and automate various aspects of the pathology workflow.

This report provides a close look at AI in pathology market. It offers applications in drug discovery, disease diagnosis & prognosis, clinical workflow, and training & education.

Stakeholders

  • Pathologists
  • Suppliers And Distributors of Digital Pathology Equipment
  • AI System Providers
  • Medical Research and Biopharmaceutical Companies
  • Pharmaceutical Companies and Cros
  • Hospitals and Clinics
  • Laboratories
  • Regulatory Bodies
  • Medical Research Institutes
  • Artificial Intelligence (AI) in Pathology Solution Providers
  • Universities and Research Organizations
  • Forums, Alliances, and Associations
  • Academic Research Institutes
  • Technology Providers
  • Healthcare Payers

Report Objectives

  • To define, describe, and forecast the AI in pathology market by offering, neural networks, functions, use case, end user, and region
  • To provide detailed information about the major factors influencing the market growth (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments in North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile key players and comprehensively analyze their market shares and core competencies in the AI in pathology market
  • To benchmark players operating in the AI in pathology market using the Competitive Leadership Mapping framework, which analyzes key market players and start-ups on various parameters within the broad categories of market share/rank and product/service footprint
  • To track and analyze competitive developments such as product launches, expansions, agreements, partnerships, collaborations, product approvals, investments, and acquisitions to strengthen their market presence in the AI in pathology market.

 

Previous Versions of this Report

Al in Pathology Market by Neural Network (GAN, CNN, RNN), Function (Diagnostic, Image Analysis, CDSS, Data Management, Analytics), Use Case (Drug Discovery, Clinical workflow), End User (Hospital, Labs, Pharma/Biotech), & Region - Global Forecast to 2029

Report Code HIT 8721
Published in Nov, 2024, By MarketsandMarkets™

Al in Pathology Market by Neural Network (GAN, CNN, RNN), Function (Diagnostic, Image Analysis, CDSS, Data Management, Analytics), Use Case (Drug Discovery, Clinical workflow), End User (Hospital, Labs, Pharma/Biotech), & Region - Global Forecast to 2029

Report Code HIT 8721
Published in Jul, 2023, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Al in Pathology Market

DMCA.com Protection Status